- NCIt
- C147561
Loading cancer entity…
Loading cancer entity…
Clinical trials
109 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06315491 | A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | terminated | Phase 2 | 40 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 40 | Sonnet BioTherapeuticsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT02364713 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
| terminated |
| Phase 2 |
| 17 |
| Mayo ClinicOTHER |
| 1 |
| Dec 11, 2025 |
| clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | terminated | Phase 2 / Phase 3 | 600 | Sutro Biopharma, Inc.INDUSTRY | 7 | Sep 23, 2025 | clinicaltrials |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | terminated | Phase 2 / Phase 3 | 70 | Mateon TherapeuticsINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Apr 18, 2024 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer(SEASCAPE) | terminated | Phase 1 / Phase 2 | 35 | Aduro Biotech, Inc.INDUSTRY | 2 | Apr 4, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials